NEW YORK (GenomeWeb News) – Epic Sciences, which is developing diagnostics to identify and characterize rare cells, said today it is collaborating with six drug manufacturers to develop companion diagnostic tools.

The San Diego-based company declined to identify its drug manufacturer partners, but Genentech, Pfizer, and Celgene have previously disclosed working relationships with Epic.

A company spokesperson declined to elaborate on the nature of the work being done but said that targeted cancers include breast, lung, prostate, pancreatic, and ovarian cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.